Skip Navigation

DRUG RECORD

 

BICTEGRAVIR

OVERVIEW
Bictegravir

 

Introduction

Bictegravir is a human immunodeficiency virus (HIV) integrase strand transfer inhibitor, the fourth in this class of agents that target the viral integrase.  Bictegravir is used only in combination with other antiretroviral agents in the treatment of HIV infection and it has had limited use.  Bictegravir is associated with a low rate of serum aminotransferase elevations during therapy, but has not been linked to instances of acute, clinically apparent liver injury.

 

Background

Bictegravir (bic teg' ra vir) is a relatively new antiretroviral drug that targets the HIV integrase, one of the three viral enzymes involved in replication.  Bictegravir blocks the binding site of the HIV integrase and prevents the strand transfer activity and integration of the provirus into the host genome.  Bictegravir has both in vitro and in vivo activity against HIV, and several randomized controlled trials have shown that it in combination with other antiretroviral agents can cause significant declines in HIV RNA levels and rises in peripheral CD4 T cell counts, demonstrating non-inferiority to established combination antiretroviral regimens of proven efficacy.  Bictegravir (50 mg) in a fixed combination with emtricitabine (200 mg) and tenofovir alafenamide (25 mg) under the brand name Biktarvy was approved for use in HIV infection in the United States in 2018 and is currently used in an increasing proportion of antiretroviral regimens.  The recommended dose is one tablet daily.  Unlike the other integrase strand transfer inhibitors, bictegravir has not been marketed by itself to allow combination with other antiretroviral agents.  Combination of Biktarvy with other antiretroviral agents is not recommended nor its use in patients with severe renal or liver dysfunction.  While generally well tolerated, bictegravir therapy may be accompanied by diarrhea, headache, nausea and fever.

 

Hepatotoxicity

In large clinical trials, therapy with bictegravir combined with emtricitabine and tenofovir alafenamide was associated with alanine aminotransferase (ALT) elevations (above 1.5 times ULN) in 11% patients, but these rates were similar to those in comparator groups (12% to 15%) receiving matched background optimized antiretroviral therapy without bictegravir.  Elevations above 5 times ULN occurred in only 1.4% of bictegravir vs 0.9% to 1.3% of control comparator arm subjects.  The elevations were not associated with clinical symptoms and generally did not require dose modification.  In addition, there were no instances of acute hepatocellular liver injury with jaundice.  The product label for bictegravir mentions acute exacerbations of hepatitis B and hepatic failure as potential adverse reactions when bictegravir with emtricitabine and tenofovir is discontinued.  This adverse reaction can occur upon discontinuation of any antiretroviral regimen with concurrent activity against HBV and represents the effects of tenofovir and emtricitabine.  Nevertheless, since its approval and its more widescale use, there have been no published reports of clinically apparent cases of liver injury or exacerbation of hepatitis B convincingly attributed to bictegravir.

Likelihood score: E* (unproven but suspected potential cause of liver injury).

 

Mechanism of Injury

The mechanism by which bictegravir might cause liver injury is not known.  Bictegravir is metabolized by the liver, largely by glucuronidation with subsequent urinary clearance.  Bictegravir has little or no effect on microsomal cytochrome P450 enzymes.  Reconstitution of immune reactivity by antiretroviral therapy in patients with an underlying chronic hepatitis B or C can be associated with a transient flare of hepatitis.  Discontinuation of antiretroviral therapy with concurrent activity against HBV can cause severe exacerbations of hepatitis B.

 

Outcome and Management

If bictegravir hepatotoxicity occurs, it must be rare. Bictegravir has not been linked to cases of acute liver failure, chronic hepatitis or vanishing bile duct syndrome.  Patients receiving antiviral therapy for HIV infection should be screened for evidence of hepatitis B and C and treated accordingly.

 

Drug Class:  Antiviral Agents

 

Other Drugs in the Subclass, Integrase Strand Transfer Inhibitors:  Dolutegravir, Elvitegravir, Raltegravir

 

Top of page

 

PRODUCT INFORMATION

Bictegravir


REPRESENTATIVE TRADE NAMES
Bictegravir – Biktarvy®
(Bictegravir, Emtricitabine and Tenofovir Alafenamide Combination Product)


DRUG CLASS
Antiviral Agents


COMPLETE LABELING

Product labeling at DailyMed, National Library of Medicine, NIH

 

Top of page

 

DRUG CAS REGISTRY NO MOLECULAR FORMULA STRUCTURE
Bictegravir 1611493-60-7 C21-H18-F3-N3-O5 Bictegravir chemical structure
Dolutegravir 1051375-16-6 C20-H19-F2-N3-O5 Dolutegravir chemical structure
Elvitegravir 697761-98-1 C23-H23-Cl-F-N-O5 Elvitegravir Chemical Structure
Raltegravir 518048-05-0 C20-H21-F-N6-O5 Raltegravir Chemical Structure

Top of page


 

References updated: 10 April 2019

  1. Núñez M. Hepatic toxicity of antiviral agents. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 505-18.  (Review of hepatotoxicity of antiviral agents including drugs for HIV infection, although the integrase strand transfer inhibitors are not discussed).

  2. Flexner C. Antiretroviral agents and treatment of HIV infection. In, Brunton LL, Hillal-Dandan R, Knollman BC, eds. Goodman & Gilman’s the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 1137-57.  (Textbook of pharmacology and therapeutics).

  3. http://aidsinfo.nih.gov/guidelines  (Regularly updated clinical guidelines on the use of antiretroviral agents in HIV-1 infected adults, adolescents and children).

  4. Cocohoba J, Dong BJ. Raltegravir: the first HIV integrase inhibitor. Clin Ther 2008; 30: 1747-65. PubMed Citation  (Review of the mechanism of action, pharmacokinetics and phase I-III studies of raltegravir; in combined phase III studies, ALT elevations above 5 times ULN occurred in 4.3% of 462 raltegravir treated vs 3.4% of 237 placebo treated patients who were receiving optimized background therapy; no hepatic serious adverse events were reported).

  5. Surgers L, Lacombe K. Hepatoxicity of new antiretrovirals: a systematic review. Clin Res Hepatol Gastroenterol 2013; 37: 126-33. PubMed Citation  (Review of evidence of liver injury in large clinical trials of newer antiretroviral agents including dolutegravir but not bictegravir concluded that "the overall hepatic tolerance is far better with the novel drugs in this review than with former ARV regimens"; ALT elevations occurred with equal frequency in dolutegravir and comparator arms, and one patient on raltegravir developed DRESS syndrome).

  6. Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52. PubMed Citation  (Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 12 [1.3%] cases were attributed to antiretroviral agents, but none to the integrase inhibitors–dolutegravir, elvitegravir, raltegravir or bictegravir).

  7. Sax PE, Pozniak A, Montes ML, Koenig E, DeJesus E, Stellbrink HJ, Antinori A, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet 2017; 390 (10107): 2073-82. PubMed Citation  (Among 657 previously untreated adults with HIV infection who were started on combination antiretroviral therapy with bictegravir or dolutegravir with tenofovir and emtricitabine, HIV RNA suppression was similar in the two groups [89% vs 93%] as were the rates of adverse events, including ALT levels above 5 times ULN [2% vs 1%] which were usually attributable to concurrent hepatitis B or C).

  8. Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet 2017; 390 (10107): 2063-72. PubMed Citation  (Among 631 adults with previously untreated HIV infection started on single tablet regimens, viral control [HIV RNA <500 copies/mL] at 48 weeks was similar with bictegravir/emtricitabine/tenofovir [92%] as with dolutegravir/abacavir/lamivudine [93%], while adverse event rates were slightly less, including discontinuations for adverse events [0% vs 1.3%], serious adverse events [6% vs 8%] and ALT elevations above 5 times ULN [0.6% vs 1.3%]).

  9. Daar ES, DeJesus E, Ruane P, Crofoot G, Oguchi G, Creticos C, Rockstroh JK, et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48-week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV 2018; 5: e347-e356. PubMed Citation  (Among 577 adults with HIV infection switched to Biktarvy [bictegravir/ emtricitabine/ tenofovir] or maintained on previous combination regimen, HIV RNA suppression was similar in the two groups, as were overall as well as serious adverse event rates, ALT elevations above 5 times ULN occurring in 1% vs 2%).

  10. Molina JM, Ward D, Brar I, Mills A, Stellbrink HJ, López-Cortés L, Ruane P, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48-week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV 2018; 5: e357-e365. PubMed Citation  (Among 563 adults with HIV infection switched to bictegravir/emtricitabine/tenofovir or maintained on previous combination regimen, HIV RNA suppression was similar in the two groups [both 99%], as were overall [80% vs 80%] as well as serious adverse event rates [5% vs 8%], ALT elevations above 5 times ULN occurring in 2% vs 0%, all abnormalities occurring in patients with underlying pre-existing liver disease).

  11. Markham A. Bictegravir: first global approval. Drugs 2018; 78: 601-6. PubMed Citation  (Review of the mechanism of action, history of development, pharmacology, clinical efficacy and safety of bictegravir; mentions that elevations in serum ALT levels above 5 times ULN occurred in 1-2% of patients treated with bictegravir in clinical trials).

  12. Biktarvy--another INSTI-based combination for HIV. Med Lett Drugs Ther 2018; 60 (1553): 132-5. PubMed Citation  (Concise review of the mechanism of action, efficacy, safety and costs of bictegravir combined with tenofovir and emtricitabine [Biktarvy]; mentions the flares of hepatitis B in co-infected subjects can occur when the combination is stopped).

Top of page


OTHER REFERENCE LINKS
Bictegravir
  1. PubMed logoRecent References on Bictegravir

  2. Clinical Trials logoTrials on Bictegravir

Top of page